Novartis AG

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study (2018) Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3) (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Gaillez C, Fasth AE Conference contribution A matter of perspective: Imputation methods and their effects illustrated with the use of data from the PRIME study (2018) Reich K, Bachhuber T, Melzer N, Sieder C, Sticherling M Conference contribution From relative to absolute treatment outcomes-Correlation of PASI 90 and PASI <= 2 in three clinical trials with secukinumab (2018) Reich K, Bachhuber T, Melzer N, Sieder C, Sticherling M Conference contribution From relative to absolute Treatment Goals - Correlation of PASI 90 and PASI <=2 in three clinical Studies with Secukinumab (2018) Reich K, Bachhuber T, Melzer N, Sieder C, Sticherling M Conference contribution SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2018) Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al. Conference contribution Individualised treatment targets in patients with type-2 diabetes and hypertension (2018) Schmieder R, Tschoepe D, Koch C, Ouarrak T, Gitt AK Journal article Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study (2018) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Journal article